- Conditions
- Colorectal Cancer
- Interventions
- fluorouracil, leucovorin calcium, levamisole hydrochloride
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2005
- U.S. locations
- 57
- States / cities
- Scottsdale, Arizona • Palo Alto, California • San Francisco, California + 48 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 721–744
of 10,627
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Select Advanced Solid Tumors
- Interventions
- IMC-C103C, Atezolizumab
- Drug
- Lead sponsor
- Immunocore Ltd
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more
- Conditions
- Interstitial Lung Disease (ILD), Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Not listed
- Lead sponsor
- Pulmonary Fibrosis Foundation
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 2,004 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
- Conditions
- Breast Cancer
- Interventions
- letrozole, Blood Collection, biopsy/lumpectomy/mastectomy
- Drug · Other · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Tulsa, Oklahoma • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Epilepsy, Benign Neonatal
- Interventions
- Phenobarbital Sodium Injection
- Drug
- Lead sponsor
- NEMA Research, Inc.
- Industry
- Eligibility
- 34 Weeks to 44 Weeks
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 7
- States / cities
- Little Rock, Arkansas • Washington D.C., District of Columbia • Miami, Florida + 3 more
- Conditions
- Melanoma
- Interventions
- Epacadostat, ipilimumab
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Miami, Florida • Tampa, Florida + 4 more
- Conditions
- Childhood Obesity
- Interventions
- Aerobic Exercise, Resistance Exercise, Aerobic and Resistance Exercise
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Plaque Psoriasis
- Interventions
- Ixekizumab, Guselkumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,027 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 98
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 82 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Rosiglitazone
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Tempe, Arizona • Fullerton, California + 48 more
- Conditions
- Critical Illness
- Interventions
- Revealed Alerts, Unrevealed Alerts
- Device
- Lead sponsor
- David T Huang
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 7,445 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Interventions
- Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Capivasertib, Cediranib Maleate, Computed Tomography, Durvalumab, Echocardiography Test, Multigated Acquisition Scan, Olaparib
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 760
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 481 more
- Conditions
- Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Lumbar Puncture, Positron Emission Tomography, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 363 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 634
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 433 more
- Conditions
- Sleep Disorders, Physical Activity, Depression, Anxiety
- Interventions
- Family Check Up
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 10 Years to 13 Years
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Dehydration, Electrolyte Imbalance, Electrolyte Depletion, Fluid and Electrolyte Imbalance
- Interventions
- Buoy Electrolyte, Water only, Nuun Electrolyte
- Dietary Supplement · Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Pulmonary Artery Stenosis
- Interventions
- Transcatheter Cutting Balloon therapy, High Pressure Balloon Angioplasty
- Device · Procedure
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 0 Years to 18 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 6
- States / cities
- San Francisco, California • Boston, Massachusetts • Durham, North Carolina + 3 more
- Conditions
- HER2-positive Advanced Solid Tumor
- Interventions
- DB-1303/BNT323, Pertuzumab Injection, Ritonavir, Itraconazole
- Biological · Drug
- Lead sponsor
- DualityBio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 796 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 35
- States / cities
- Cerritos, California • Los Angeles, California • San Diego, California + 29 more
- Conditions
- Meningeal Neoplasms
- Interventions
- Intrathecal (injected into the spinal fluid) DepoCyt, Intrathecal methotrexate, Intrathecal cytarabine (also known as ara-C)
- Drug
- Lead sponsor
- Pacira Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Berkeley, California • Los Angeles, California + 18 more
- Conditions
- Bradycardia, Sinus Node Dysfunction, Heart Block, Syncope, Cardiomyopathies, Ventricular Tachycardia, Heart Failure
- Interventions
- Physiologic pacing device implant
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 870 participants
- Timeline
- 2018 – 2021
- U.S. locations
- 26
- States / cities
- Huntsville, Alabama • Burlingame, California • San Diego, California + 22 more
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Fatigue, Neurotoxicity Syndrome, Obesity, Stage I Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Carboplatin, Intensity-Modulated Radiation Therapy, Internal Radiation Therapy, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
- Radiation · Drug · Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 601 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 533
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 352 more
- Conditions
- Melanoma (Skin), Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- hu14.18-IL2 fusion protein
- Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 54
- States / cities
- Little Rock, Arkansas • Duarte, California • La Jolla, California + 44 more
- Conditions
- Sarcoma
- Interventions
- Trivalent ganglioside vaccine, OPT-821
- Biological
- Lead sponsor
- MabVax Therapeutics, Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Denver, Colorado • Atlanta, Georgia + 10 more
- Conditions
- Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer
- Interventions
- Bevacizumab, Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study
- Biological · Other · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 5
- States / cities
- Westwood, Kansas • Detroit, Michigan • Buffalo, New York + 2 more
- Conditions
- Carotid Artery Diseases, Aortic Diseases, Peripheral Arterial Diseases
- Interventions
- Intergard Standard - Collagen Coated Vascular Grafts and Patches, Hemashield - Collagen Coated Vascular Grafts and Patches, Intergard Silver - Antimicrobial Collagen Coated Vascular Grafts and Patches, Intergard Synergy - Antimicrobial Collagen Coated Vascular Grafts
- Device
- Lead sponsor
- Intervascular
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Hershey, Pennsylvania • Pittsburgh, Pennsylvania
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Metformin immediate release (IR), Saxagliptin, Metformin IR, Saxagliptin/Metformin XR FDC, Metformin XR
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 7
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Louisville, Kentucky + 3 more